Title
Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users
UMMS Affiliation
Department of Psychiatry
Publication Date
1995-11-01
Document Type
Article
Subjects
Adult; Amantadine; Buprenorphine; *Cocaine; Desipramine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Narcotic Antagonists; Substance Abuse Detection; Substance-Related Disorders; Treatment Outcome
Disciplines
Psychiatry
Abstract
The clinical efficacy of promising cocaine anti-craving medications was examined in combination with buprenorphine. Twenty-one opioid-dependent cocaine abusers were enrolled in a double-blind, 12-week trial in which they received on a daily basis buprenorphine (8 mg, s.l.) plus either desipramine (150 mg, p.o.), amantadine (300 mg, p.o.), or fluoxetine (60 mg, p.o.). Urine samples and self-reported drug use were obtained 1-3 times/week. The order of greatest patient retention across the 12 weeks was desipramine (83.3%) > amantadine (66.7%) > fluoxetine (20.0%). The desipramine and amantadine groups appeared to have greater increases in opioid- and cocaine-free urines than the fluoxetine group. These results suggest that desipramine and amantadine may facilitate greater opioid and cocaine abstinence than fluoxetine.
Source
J Subst Abuse Treat. 1995 Nov-Dec;12(6):423-8.
Journal/Book/Conference Title
Journal of substance abuse treatment
Related Resources
PubMed ID
8749726
Repository Citation
Oliveto A, Kosten TR, Schottenfeld RS, Falcioni J, Ziedonis DM. (1995). Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. Psychiatry Publications and Presentations. Retrieved from https://escholarship.umassmed.edu/psych_pp/169